Equities analysts forecast that Global Blood Therapeutics Inc (NASDAQ:GBT) will announce ($0.88) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Global Blood Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.01) and the highest estimate coming in at ($0.72). Global Blood Therapeutics posted earnings of ($0.94) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 6.4%. The business is scheduled to report its next quarterly earnings results on Tuesday, February 26th.
On average, analysts expect that Global Blood Therapeutics will report full year earnings of ($3.36) per share for the current fiscal year, with EPS estimates ranging from ($3.49) to ($3.20). For the next fiscal year, analysts forecast that the business will report earnings of ($3.76) per share, with EPS estimates ranging from ($4.24) to ($3.03). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that cover Global Blood Therapeutics.
Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings data on Tuesday, November 6th. The company reported ($0.83) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.85) by $0.02. During the same quarter last year, the company posted ($0.66) EPS.
Several research firms have recently issued reports on GBT. Cowen reiterated a “buy” rating and issued a $83.00 target price on shares of Global Blood Therapeutics in a research note on Monday, August 13th. Wedbush reiterated a “buy” rating and issued a $73.00 target price on shares of Global Blood Therapeutics in a research note on Monday, November 19th. Cantor Fitzgerald set a $96.00 target price on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 23rd. BidaskClub upgraded shares of Global Blood Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, October 19th. Finally, Oppenheimer set a $82.00 target price on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, November 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $83.20.
GBT traded down $4.02 during trading on Monday, hitting $42.66. 4,168,610 shares of the company’s stock were exchanged, compared to its average volume of 1,565,665. Global Blood Therapeutics has a fifty-two week low of $30.15 and a fifty-two week high of $68.05. The company has a market cap of $2.44 billion, a price-to-earnings ratio of -15.45 and a beta of 3.65.
A number of institutional investors and hedge funds have recently bought and sold shares of GBT. Focused Wealth Management Inc bought a new position in Global Blood Therapeutics during the third quarter valued at about $104,000. PNC Financial Services Group Inc. grew its position in Global Blood Therapeutics by 740.3% during the third quarter. PNC Financial Services Group Inc. now owns 4,353 shares of the company’s stock valued at $165,000 after buying an additional 3,835 shares during the period. Rehmann Capital Advisory Group bought a new position in Global Blood Therapeutics during the third quarter valued at about $165,000. Tiverton Asset Management LLC bought a new position in Global Blood Therapeutics during the second quarter valued at about $166,000. Finally, Quantitative Systematic Strategies LLC bought a new position in Global Blood Therapeutics during the second quarter valued at about $203,000.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Recommended Story: Bear Market
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.